Data on grants for biomedical research by 10 major funders of health research were collected from the World RePORT platform to explore what is being funded, by whom and where. This analysis is part of the World Health Organization Global Observatory on Health Research and Development’s work with the overall aim to enable evidence-informed deliberations and decisions on new investments in health research and development. The analysis expands on the interactive data visualisations of these data on the Observatory’s website and describes the methods used to enable the categorisation of grants by health categories using automated data-mining techniques. Grants data were extracted from the World RePORT platform for 2016, the most recent year with data from all funders. A data-mining algorithm was developed in Java to categorise grants by health category. The analysis explored the distribution of grants by funder, recipient country and organisation, type of grant, health category, average grant duration, and the nature of collaborations between recipients of direct grants and the institutions they collaborated with. Out of a total of 69,420 grants in 2016, the United States of America’s National Institutes of Health funded the greatest number of grants (52,928; 76%) and had the longest average grant duration (6 years and 10 months). Grants for research constituted 70.4% (48,879) of all types of grants, followed by grants for training (13,008; 18.7%) and meetings (2907; 4.2%). Of grant recipients by income group, low-income countries received only 0.2% (165) of all grants. Almost three-quarters of all grants were for non-communicable diseases (72%; 40,035), followed by communicable, maternal, perinatal and nutritional conditions (20%; 11,123), and injuries (6%; 3056). Only 1.1% of grants were for neglected tropical diseases and 0.4% for priority diseases on the WHO list of highly infectious (R&D blueprint) pathogens. The findings highlight the importance of considering funding decisions by other actors in future health research and capacity-strengthening decisions. This will not only improve efficiency and equity in allocating scarce resources but will also allow informed investment decisions that aim to support research on public health needs and neglected areas.

中文翻译：

---

生物医学研究的资源分配：主要资助者的投资分析

从世界报告平台上收集了10个主要卫生研究资助者为生物医学研究提供的赠款数据，以探索由谁，何地，何地资助什么。这项分析是世界卫生组织全球卫生研究与发展观察所工作的一部分，其总体目标是就卫生研究与开发方面的新投资进行有据可依的讨论和决策。该分析扩展了天文台网站上这些数据的交互式数据可视化效果，并描述了用于使用自动数据挖掘技术按健康类别对补助金进行分类的方法。赠款数据是从2016年World RePORT平台中提取的，最近一年的数据来自所有资助者。用Java开发了一种数据挖掘算法，以按健康类别对补助金进行分类。该分析探讨了资助者，资助国和组织的赠款分布，赠款类型，卫生类别，平均赠款期限以及直接赠款的受赠人和与之合作的机构之间的合作性质。在2016年的69,420笔赠款中，美国国立卫生研究院资助的赠款数量最多（52,928; 76％），平均赠款时间最长（6年零10个月）。研究补助金占所有补助金的70.4％（48,879），其次是培训补助金（13,008; 18.7％）和会议补助金（2907; 4.2％）。在按收入组别划分的赠款接受者中，低收入国家仅获得所有赠款的0.2％（165）。在所有赠款中，将近四分之三用于非传染性疾病（72％； 40035），其次是传染性，产妇，围产期和营养状况（20％； 11123）和伤害（6％； 3056）。在世卫组织高传染性（研发蓝图）病原体名单上，仅1.1％的赠款用于被忽视的热带病，而0.4％用于重点疾病。研究结果强调了在未来的健康研究和加强能力的决定中考虑其他参与者的资助决定的重要性。这不仅将提高分配稀缺资源的效率和公平性，还将允许作出明智的投资决定，以支持对公共卫生需求和被忽视地区的研究。3056）。在世卫组织高传染性（研发蓝图）病原体名单上，仅1.1％的赠款用于被忽视的热带病，而0.4％用于重点疾病。研究结果强调了在未来的健康研究和加强能力的决定中考虑其他参与者的资助决定的重要性。这不仅将提高分配稀缺资源的效率和公平性，还将允许作出明智的投资决定，以支持对公共卫生需求和被忽视地区的研究。3056）。在世卫组织高传染性（研发蓝图）病原体名单上，仅1.1％的赠款用于被忽视的热带病，而0.4％用于重点疾病。研究结果强调了在未来的健康研究和加强能力的决定中考虑其他参与者的资助决定的重要性。这不仅将提高分配稀缺资源的效率和公平性，还将允许作出明智的投资决定，以支持对公共卫生需求和被忽视地区的研究。